Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitri P Mikhailidis

Showing results (171-180 of 675) with videos related to

Pageof 68
Sort By:
The Open Cardiovascular Medicine Journal|June 11, 2011
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentVasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, et al.
Current Medical Research and Opinion|February 1, 2011
Ezetimibe and low density lipoprotein subfractions: an ongoing debateNiki Katsiki, Vasilis G Athyros, Asterios Karagiannis, et al.
Current Vascular Pharmacology|January 26, 2012
Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.
Endocrine-Related Cancer|November 30, 2007
Pheochromocytoma: an update on genetics and managementAsterios Karagiannis, Dimitri P Mikhailidis, Vasilios G Athyros, et al.
Angiology|September 17, 2014
Contrast-Induced Nephropathy: An "All or None" Phenomenon?Niki Katsiki, Vasilios G Athyros, Asterios Karagiannis, et al.
Expert Review of Clinical Pharmacology|January 6, 2018
Dyslipidaemia in the elderly: to treat or not to treat?Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez, et al.
Vascular and Endovascular Surgery|July 25, 2009
The GALA trial: will it influence clinical practice?Kosmas I Paraskevas, Dimitri P Mikhailidis, Peter R F Bell
Current Medical Research and Opinion|February 13, 2009
JUPITER: major implications for vascular risk assessmentKonstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, et al.
Lancet (London, England)|August 18, 2009
Drug-induced fibrotic valvular heart diseaseSanjeev Bhattacharyya, Anthony H Schapira, Dimitri P Mikhailidis, et al.
Expert Opinion on Drug Safety|June 18, 2010
Atorvastatin: safety and tolerabilityVasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, et al.
Pageof 68

Showing results (171-180 of 675) with videos related to

Sort By:
Pageof 68
The Open Cardiovascular Medicine Journal|June 11, 2011
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentVasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, et al.
Current Medical Research and Opinion|February 1, 2011
Ezetimibe and low density lipoprotein subfractions: an ongoing debateNiki Katsiki, Vasilis G Athyros, Asterios Karagiannis, et al.
Current Vascular Pharmacology|January 26, 2012
Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.
Endocrine-Related Cancer|November 30, 2007
Pheochromocytoma: an update on genetics and managementAsterios Karagiannis, Dimitri P Mikhailidis, Vasilios G Athyros, et al.
Angiology|September 17, 2014
Contrast-Induced Nephropathy: An "All or None" Phenomenon?Niki Katsiki, Vasilios G Athyros, Asterios Karagiannis, et al.
Expert Review of Clinical Pharmacology|January 6, 2018
Dyslipidaemia in the elderly: to treat or not to treat?Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez, et al.
Vascular and Endovascular Surgery|July 25, 2009
The GALA trial: will it influence clinical practice?Kosmas I Paraskevas, Dimitri P Mikhailidis, Peter R F Bell
Current Medical Research and Opinion|February 13, 2009
JUPITER: major implications for vascular risk assessmentKonstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, et al.
Lancet (London, England)|August 18, 2009
Drug-induced fibrotic valvular heart diseaseSanjeev Bhattacharyya, Anthony H Schapira, Dimitri P Mikhailidis, et al.
Expert Opinion on Drug Safety|June 18, 2010
Atorvastatin: safety and tolerabilityVasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, et al.
Pageof 68